Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Avalo Therapeutics Q3 2026 Results: Net Loss of $18.9M, Loss Narrows

Avalo Therapeutics reported its quarterly financial results for the period ended September 30, 2026, highlighting the continued clinical development of its lead immunology assets. The filing details research and development expenses, net losses, and the company's current liquidity position as it pursues key pipeline milestones.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Profit before tax-18.9-30.6
Net income-18.9-30.6
EPS (diluted, $ a share)$-0.34$-2.19

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: AVTX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Avalo Therapeutics, Inc.: key numbers

Share price
$7.13Close, Nov 17
Market cap
$412M
Shares outstanding
57.82MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Avalo Therapeutics, Inc.

All →
8:07 AM ET 8-K
Capital Raise

Avalo Therapeutics Capital Raise

Avalo Therapeutics entered into an at-the-market (ATM) sales agreement with Jefferies LLC to establish a program for the potential issuance and sale of up to $200 million of common stock. Simultaneously, the company terminated its existing sales agreement with TD Securities (USA) LLC (formerly TD Cowen) that had been in place since June 2025.

Counterparty
Jefferies LLC
7:08 AM ET 8-K
Financial Results

Avalo Therapeutics Financial Results

Avalo Therapeutics reported its third quarter 2026 financial results, highlighting a cash position of $462.8 million which is expected to fund operations into 2029. The company is advancing its lead candidate, abdakibart, toward a Phase 3 program in hidradenitis suppurativa with initiation planned for the first half of 2027.

“LOTUS provides a strong clinical foundation for advancing abdakibart toward registrational development in hidradenitis suppurativa. The efficacy and safety results observed across both dosing regimens, together with the potential for once-monthly administration, give us confidence in abdakibart’s potential to become an important new treatment option for patients with HS.”

Garry Neil, MD, Chief Executive Officer
4:11 PM ET Form 4
Insider Selling

Avalo Therapeutics CFO Christopher Ryan Sullivan Sells $202K of Stock

Christopher Ryan Sullivan, CFO, sold 12,394 shares of Avalo Therapeutics, Inc. at $16.33 a share, worth $202K in total on Sep 16, 2026. Shares held after the trade: 39,900 (-23.7%).

Value
$202K
Shares
12,394
Price
$16.33
Role
CFO
Holding change
-23.7%
Trade date
Sep 16, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.